- MedTAS has launched myMedtas-Care, a new in-pharmacy programme designed to place community pharmacists at the centre of care for patients with inflammatory bowel disease (IBD) following the PBS listing of the ustekinumab biosimilar WEZLANA® on 1 July 2026.
- WEZLANA, manufactured by Amgen, is the first ustekinumab biosimilar to achieve PBS listing across all product formats — the 130 mg vial, 45 mg vial, 45 mg pre-filled syringe, and 90 mg pre-filled syringe — providing complete parity with the originator, Stelara®.
- A new streamlined authority code (item 15397J) has been introduced for the 45 mg vial used in severe Crohn's disease continuing treatment, standardising administrative requirements across vial and pre-filled syringe formats.
- The myMedtas-Care programme enables credentialled community pharmacists to administer subcutaneous ustekinumab injections or coach patients in self-injection, with features including digital patient enrolment, Quality Use of Medicines check-ins, and automated appointment reminders to support adherence.
- Participation in myMedtas-Care is free for pharmacies, with onboarding supported by the MedTAS team and accessible via www.mymedtas-care.com.au.
SYDNEY, AUSTRALIA — July 2026
Following the PBS listing of WEZLANA® (ustekinumab) on 1 July, MedTAS has launched myMedtas-Care — a first-of-its-kind, in-pharmacy program that returns pharmacists to the centre of community IBD patient care. As home delivery models have grown, many patients living with inflammatory bowel disease have lost the regular, face-to-face clinical community touchpoint that a pharmacist provides; myMedtas-Care: WEZLANA, re-establishes that connection, embedding the pharmacist back into the ongoing care of patients on ustekinumab.
Aligned with Australia's expanding pharmacist scope of practice, myMedtas-Care lets credentialled community pharmacists administer subcutaneous ustekinumab injections for patients — or coach those who want to self-inject at home — setting a new standard of care beyond self-administration alone.
WEZLANA, manufactured by Amgen, is a biosimilar to Stelara®, and the first ustekinumab biosimilar to be PBS-listed across all product formats — the 130 mg vial, 45 mg vial, 45 mg pre-filled syringe, and 90 mg pre-filled syringe — achieving complete format parity with the originator.1,2
For pharmacists, this means every ustekinumab presentation currently relied on is available and PBS-listed, giving patients and prescribers full confidence to transition to WEZLANA® across all indications and PBS listings.2
New Streamlined Authority Code
In addition to presentation equivalence across vial and pre‑filled syringe formats, WEZLANA includes a streamlined authority code (item 15397J) for the 45 mg vial used in severe Crohn’s disease continuing treatment. This update aligns the authority code for vial presentations with that already established for pre‑filled syringes, standardising administrative requirements across formats.2
Expanded Scope of Practice: Pharmacists at the Centre of Care
The WEZLANA launch aligns with Australia’s expanding pharmacist scope of practice, enabling credentialled community pharmacists to administer subcutaneous ustekinumab injections on behalf of patients.
This creates a new standard of care for patients who previously relied only on self-administration. Under the myMedtas-Care program, participating pharmacies can now:
- Enrol patients digitally at the point of dispensing, with each administration logged for traceability and continuity of care.
- Check-in with the patient as part of Quality Use of Medicines (QUM) practice — including adherence, tolerability, and any concerns.
- Administer subcutaneous injections at the pharmacy at the patient’s scheduled dose interval, in a supported clinical environment.
- Deliver automated appointment reminders, reducing the possibility of missed doses and helping to support long-term adherence.
“The PBS listing of WEZLANA is a real step forward for patients. It gives prescribers a biosimilar of ustekinumab that covers every format of the originator, accessed through the streamlined authority pathway and supported by a pharmacy injection service built around keeping patients on therapy.”
— Mohit Gupta, Chief Executive Officer & Founder, MedTAS
myMedtas-Care: A New Standard in Pharmacy-Partnered Support
myMedtas-Care, supports the central role pharmacists play in biosimilar uptake, patient education, and adherence. The program is built in genuine partnership with pharmacy — designed to integrate with existing dispensing workflows, while driving value for IBD patients.
There is no cost to participating pharmacies. Onboarding is supported by the MedTAS team and accessible via www.mymedtas-care.com.au.
About WEZLANA® (ustekinumab)
- WEZLANA is a ustekinumab biosimilar that is now PBS listed for complex refractory Fistulising Crohn’s disease, moderate to severe Ulcerative Colitis, severe Crohn’s Disease, severe Chronic plaque Psoriasis, severe psoriatic arthritis. The listing is Authority required. Wezlana is registered by the Therapeutic Goods Administration (TGA) for the treatment of adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severe active Crohn’s disease, and moderately to severe active ulcerative colitis. It is also indicated for moderate-to-severe plaque psoriasis in children and adolescent patients from 6 years of age.1 WEZLANA is manufactured by Amgen.
WEZLANA is contraindicated in patients with severe hypersensitivity to ustekinumab or any excipient, and in those with clinically important active infections. As a selective immunosuppressant, WEZLANA carries important precautions: serious bacterial, fungal and viral infections — including reactivation of latent tuberculosis — have been reported, and treatment should be withheld until any serious infection has resolved. Clinically significant risks include non‑infectious pneumonias, malignancies, serious hypersensitivity and infusion‑related reactions, Immunisations and serious skin conditions and rare cases of posterior reversible encephalopathy syndrome (PRES). Some common adverse events observed with ustekinumab include upper respiratory tract infections, headache, dizziness and injection site erythema or pain, while serious events may include serious hypersensitivity reactions, skin carcinomas, and cardiovascular events.1
Please refer to the full WEZLANA Product Information before prescribing or dispensing, available at: WEZLANA - Product Information.
About Medtas
MedTAS Pty Ltd is an Australian specialty pharmaceutical company holding commercialisation rights for WEZLANA (ustekinumab) in Australia. MedTAS partners with pharmacy networks, specialist clinicians and health technology platforms to help support patients on complex biologic therapies.
About myMedtas-Care
myMedtas-Care is the patient and pharmacy support program for WEZLANA, delivered by MedTAS in partnership with community pharmacy. The program provides pharmacist-administered injection services, patient enrolment and registration via the KomplAI platform, cold-chain storage on behalf of patients, and ongoing adherence support for Australians prescribed ustekinumab therapy.
Media Enquiries
Vicky Stavroulakis
MedTAS Pty Ltd
PBS Information: Streamline Authority. Refer to PBS Schedule for full Authority Information.
Refer to the full Product Information before dispensing, available from Amgen ph:1800 803 638 or by visiting www.amgenmedinfo.com.au. For Medical Information enquiries or for reporting adverse events, please call 1800 803 638. References: 1. Wezlana Prododuct Information available from https://wwwtga.gov.au/sites/default/files/2024-06/auspar-wezlana-240618-pi.pdf 2. PBS listing: https://www.pbs.gov.au/search?term=wezlana&analyse=false&search-type=medicines.
WEZLANA is a registered trademark of Amgen Inc. Amgen Australia Pty Ltd. ABN 31 051 057 428. Level 11, 10 Carrington Street, Sydney, NSW, 2000. MedTAS Pty Ltd. ABN 72 644 270 860. Level 12, 347 Kent Street, Sydney, NSW, 2000. MED-TAS-0012. AUS-654-26-80020. Date of Preparation: July 2026. PBS: Pharmaceutical Benefit Scheme
About us:
MedTAS Pty Ltd is an Australian specialty pharmaceutical company holding commercialisation rights for WEZLANA (ustekinumab) in Australia. MedTAS partners with pharmacy networks, specialist clinicians and health technology platforms to help support patients on complex biologic therapies.
Contact details:
Vicky Stavroulakis
